Neurelis Shows Impressive Growth and Innovations in Business Update for 2025 Neurelis, Inc. reports impressive growth in 2025, doubling revenue and expanding the VALTOCO portfolio. This update emphasizes their dedication to improving epilepsy care.

Neurelis Shows Impressive Growth and Innovations in Business Update for 2025 #United_States #San_Diego #Epilepsy #Neurelis #VALTOCO

Neurelis Showcases Promising Clinical Data at American Epilepsy Society Meeting Neurelis to present significant findings on VALTOCO® at the American Epilepsy Society's Annual Meeting, highlighting its efficacy in treating seizures.

Neurelis Showcases Promising Clinical Data at American Epilepsy Society Meeting #United_States #Atlanta #Epilepsy #Neurelis #VALTOCO

Neurelis to Join Sofie's Journey: Epilepsy Awareness Day at Disneyland Resort Neurelis is participating in the 13th Annual Sofie's Journey Epilepsy Awareness Day at Disneyland, focusing on education and community support for epilepsy.

Neurelis to Join Sofie's Journey: Epilepsy Awareness Day at Disneyland Resort #United_States #Anaheim #Neurelis #VALTOCO #Epilepsy_Awareness

Neurelis to Share Promising NRL-1049 Results During Annual CCM Meeting Neurelis, Inc. will showcase findings from its Phase 1 study on NRL-1049 at the 21st International CCM Scientific Meeting, reflecting potential advances in treating CCM.

Neurelis to Share Promising NRL-1049 Results During Annual CCM Meeting #United_States #Atlanta #Neurelis #CCM #NRL-1049

Neurelis Reveals Insights on Diazepam Nasal Spray for Pediatric Seizure Treatment Neurelis, Inc. announces presentations at the Child Neurology Society Annual Meeting, highlighting crucial findings on diazepam nasal spray’s efficacy for pediatric patients with epilepsy.

Neurelis Reveals Insights on Diazepam Nasal Spray for Pediatric Seizure Treatment #United_States #Charlotte #Neurelis #VALTOCO #Pediatric_Epilepsy

Neurelis Receives FDA Approval for VALTOCO Nasal Spray for Young Children to Treat Seizures Neurelis has announced the FDA's approval of VALTOCO for young children experiencing acute seizure clusters. This nasal spray offers a vital treatment option.

Neurelis Receives FDA Approval for VALTOCO Nasal Spray for Young Children to Treat Seizures #United_States #San_Diego #FDA_Approval #Neurelis #VALTOCO

Neurelis to Present Innovative Analyses on Diazepam Treatment for Seizures at AAN Annual Meeting Neurelis, Inc. will showcase crucial analyses on the efficacy of diazepam nasal spray for seizure treatment at the upcoming AAN meeting in San Diego.

Neurelis to Present Innovative Analyses on Diazepam Treatment for Seizures at AAN Annual Meeting #United_States #San_Diego #Neurelis #AAN #Diazepam

Neurelis Unveils Research on Seizure Treatment Methods at AES Annual Meeting Neurelis, Inc. showcases significant studies on immediate-use seizure medications at this year's American Epilepsy Society Annual Meeting in Los Angeles.

Neurelis Unveils Research on Seizure Treatment Methods at AES Annual Meeting #United_States #Los_Angeles #Epilepsy #Neurelis #VALTOCO